MGC Pharmaceuticals Limited Application for Admission to Trading (8386F)
09 November 2022 - 9:20PM
UK Regulatory
TIDMMXC
RNS Number : 8386F
MGC Pharmaceuticals Limited
09 November 2022
MGC Pharmaceuticals Ltd.
Compliance Release - Application for Admission to Trading
9 November 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd (' MGC Pharma' or ' the Company ')
advises that it is applying for the admission to the Financial
Conduct Authority's Official List, and to trading on the Main
Market of the LSE for 50,200,000 Fully Paid Ordinary Shares
(Shares) issued by MGC Pharma, with the Company is seeking
admission to trading for these Shares from 8:00am (GMT) on 10
November 2022.
Details of the 50,200,000 Shares for which these applications
have been lodged are as follows:
-- 50,000,000 Shares issued to MGC employees to settle
salary/wages in lieu of cash settlement
-- 200,000 Shares issued on the exercise of securities granted
under the Company's Employee Share Scheme
--Ends--
Authorised for release by the Chairman, for further information
please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer David Lim
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.eu info@mgcpharma.eu
UK Financial and Corporate UK Broker
Advisor Turner Pope
Hannam & Partners Andy Thacker
Rupert Fane / Nilesh Patel +44 203 657 0050
+44 7810 056 104 info@turnerpope.com
rf@hannam.partners / nilesh@hannam.partners
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
bio-pharma company, focused on developing and supplying accessible
and ethically produced plant inspired medicines, combining in-house
research with innovative technologies, with the goal of finding or
producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSMZMGMGLDGZZM
(END) Dow Jones Newswires
November 09, 2022 05:20 ET (10:20 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024